Safety aspects of HIV-protease inhibitors
(Veiligheids aspecten van HIV-proteaseremmers)
2002-06-12
Doctoral Thesis
| Related Files |
|---|
View PDF Version
(020612_Dieleman, Jeanne Petra.pdf, 4.3MB) |
The objectives of this thesis were to provide more insight into the risk and risk factors of adverse drug reactions associated with HIV-protease inhibitor treatment under non-experimental everyday circumstances. By recognition of risk factors, patients at risk can be identified beforehand and risk management can be targeted more efficiently, hence ultimately improving the safety of HIV-protease inhibitor treatment. In the studies presented in this thesis we applied multiple research strategies. tn which the nationwide ATHENA cohort played a central role.
The publication of this thesis was financially supported by Abbott BV, Boehringer Ingelheim BV, Bristol-Myers Squibb BV, Glaxo Smith Kline BV, Merck Sharp & Dohme BV and Roche Pharmaceuticals BV.
- patient
- indinavir
- inhibitor
- treatment
- study
- concentration
- regimen
- plasma
- switch
- lipodystrophy
- urological symptoms
- hiv-protease
- therapy
- antiretroviral
- haart
- leukocyturia
- cohort
- symptom
- effect
- chapter
